Effect of Introducing Procalcitonin on Antimicrobial Therapy Duration in Patients With Sepsis and/or Pneumonia in the Intensive Care Unit

Annals of Pharmacotherapy

Volumn 48, Issue 5, 2014, Pages 577-583

  Bishop, Bryan M ^a   Bon, John J ^a   Trienski, Tamara L ^a   Pasquale, Timothy R ^a   Martin, Bradley R ^a   File Jr , Thomas M ^a  

^a AKRON CITY HOSPITAL   (United States)

Author keywords

antibiotic consumption; bacterial pneumonia; intensive care unit patients; procalcitonin; sepsis

Indexed keywords

ANTIINFECTIVE AGENT; PROCALCITONIN;

ADULT; ANTIMICROBIAL THERAPY; APACHE; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; FEMALE; HORMONE BLOOD LEVEL; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHYSICIAN; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; SEPSIS; TEACHING HOSPITAL; TREATMENT DURATION;

ANTIBIOTIC CONSUMPTION; BACTERIAL PNEUMONIA; INTENSIVE CARE UNIT PATIENTS; PROCALCITONIN; SEPSIS;

AGED; ANTI-INFECTIVE AGENTS; APACHE; CALCITONIN; CASE-CONTROL STUDIES; CRITICAL ILLNESS; FEMALE; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT READMISSION; PNEUMONIA; PROTEIN PRECURSORS; RECURRENCE; SEPSIS;

EID: 84898677125     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014520957     Document Type: Article

References (17)

1. Boucher HW,Talbot GH,Bradley JS, et al.Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.Clin Infect Dis. 2009;48:1-12.
2. Dellit TH,Owens RC,McGowan JE, et al.Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.Clin Infect Dis. 2007;44:159-177.
3. Harbarth S,Holeckova K,Froidevaux C, et al.Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis.Am J Respir Crit Care Med. 2001;164:396-402.
4. Maruna P,Nedelnikova K,Gurlich R.Physiology and genetics of procalcitonin.Physiol Res. 2000;49:S57-S61.
5. Schuetz P,Albrich W,Mueller B.Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present, and future.BMC Med. 2011;9:107.
6. Bouadama L,Luyt C-E,Tubach F, et al.Use of Procalcitonin to Reduce Patients' Exposure to Antibiotics in Intensive Care Units (PRORATA Trial): a multi-centre, randomized controlled trial.Lancet. 2010;375:463-474.
7. Hochreiter M,Kohler T,Schweiger AM, et al.Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial.Crit Care. 2009;13:R83.
8. Nobre V,Harbarth S,Graf J-D,Rohner P,Pugin J.Use of procalcitonin to shorten antibiotic treatment duration in septic patients.Am J Respir Crit Care Med. 2008;177:498-505.
9. Stolz D,Smyrnios N,Eggimann P, et al.Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study.Eur Respir J. 2009;34:1364-1375.
10. Procalcitonin (PCT) guidance. http://www.nebraskamed.com/app_files/pdf/careers/education-programs/asp/procalcitonin-guidance.pdf. Accessed August 24, 2012.
11. Evans HL,Lefrak SN,Lyman J, et al.Cost of gram-negative resistance.Crit Care Med. 2007;35:89-95.
12. Malhotra-Kumar S,Lammens C,Coenen S,Van Herck K,Goossens H.Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study.Lancet. 2007;369:482-490.
13. Schuetz P,Chiappa V,Briel M,Greenwald JL.Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms.Arch Intern Med. 2011;171:1322-1331.
14. Jensen JU,Hein L,Lundgren B, et al.Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial.Crit Care Med. 2011;39:2048-2058.
15. Layios N,Lambermont B,Canivet J-L, et al.Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients.Crit Care Med. 2012;40:2304-2309.
16. Foushee JA,Hope NH,Grace EE.Applying biomarkers to clinical practice: a guide for utilizing procalcitonin assays.J Antimicrob Chemother. 2012;67:2560-2569.
17. Dahaba AA,Rehak PH,List WF.Procalcitonin and c-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis.Intensive Care Med. 2003;29:579-583.